Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress

Business Wire February 27, 2020

Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference

Business Wire February 24, 2020

Sage Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

Business Wire February 10, 2020

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire February 4, 2020

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire January 3, 2020

Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020

Business Wire December 23, 2019

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened

PR Newswire December 10, 2019

Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Business Wire December 10, 2019

SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders

ACCESSWIRE IA December 9, 2019

Lost Money in Sage Therapeutics, Inc.?

Business Wire December 5, 2019

Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder

Business Wire December 5, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire December 3, 2019

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Sage Therapeutics, Inc. (SAGE) on Behalf of Shareholders

Business Wire November 25, 2019

Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

Business Wire November 12, 2019

Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference

Business Wire November 11, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire November 5, 2019

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Sage Therapeutics, Inc.- SAGE

GlobeNewswire October 30, 2019

Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Business Wire October 9, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 2, 2019

Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series

Business Wire October 2, 2019